Imam Journal of Applied Sciences

ORIGINAL ARTICLE
Year
: 2017  |  Volume : 2  |  Issue : 2  |  Page : 45--48

Efficacy of iron isomaltoside among anemic females of Bundelkhand region: An interventional study


Anupma Upadhyay1, Syed Esam Mahmood2, Meena Saxena1, Kanchan Singh1 
1 Department of Obstetrics and Gynaecology, Government Medical College, Banda, Uttar Pradesh, India
2 Department of Community Medicine, Integral Institute of Medical Sciences and Research, Lucknow, Uttar Pradesh, India

Correspondence Address:
Dr. Syed Esam Mahmood
Department of Community Medicine, Integral Institute of Medical Sciences and Research, Lucknow, Uttar Pradesh
India

Introduction: More than a quarter of the world's population is anemic with about one half of the burden from iron deficiency. The prevention and treatment of iron deficiency is a major public health goal especially in women in low-income countries. Challenges in the treatment of iron deficiency include a selection of an iron replacement product that can be given as high-dose intravenous (IV) infusion in single visit with good safety profile. In this pilot study, a new IV therapeutic agent iron isomaltoside 1000 with above-desired properties was investigated to establish its efficacy in the treatment of iron deficiency anemia (IDA). Material and Methods: This 3 months' prospective interventional hospital-based study was conducted on 42 nonpregnant women with moderate-to-severe anemia attending obstetrics and Gynecology Department at Government Medical College Banda in Bundelkhand region. Pre- and post-hemoglobin (Hb) estimation after 3 weeks of a single shot of iron isomaltoside 1000 IV infusion was done. A rise in Hb of 2 g/dl or more at 21 days was considered a satisfactory response. SPSS software 17.0 version was used for data analysis. Results: Mean preinfusion Hb was found to be 7.139 g/dl and mean postinfusion Hb was found to be 10.088 g/dl. Thus, a rise of 2.949 g/dl in mean Hb after 3 weeks was recorded after a single infusion of iron isomaltoside among the anemic females. Conclusion: Iron isomaltoside has demonstrated robust efficacy in patients suffering from IDA due to different etiologies. The wide dosing range allows iron correction in a single visit with minimal risk of anaphylaxis and is thus cost-effective for health-care system.


How to cite this article:
Upadhyay A, Mahmood SE, Saxena M, Singh K. Efficacy of iron isomaltoside among anemic females of Bundelkhand region: An interventional study.Imam J Appl Sci 2017;2:45-48


How to cite this URL:
Upadhyay A, Mahmood SE, Saxena M, Singh K. Efficacy of iron isomaltoside among anemic females of Bundelkhand region: An interventional study. Imam J Appl Sci [serial online] 2017 [cited 2021 Jan 20 ];2:45-48
Available from: https://www.e-ijas.org/article.asp?issn=2589-0603;year=2017;volume=2;issue=2;spage=45;epage=48;aulast=Upadhyay;type=0